Rare diseases
Investigational molecules
Locations
Piazza Dell' Universita' 1, 06123 Perugia, Italy
Clinical research activity includes relapsed or refractory classical Hodgkin lymphoma, with interest in treatment settings where disease has progressed after prior therapy and in patients requiring non-standard options.
The focus is on achieving deeper complete response outcomes in heavily pretreated lymphoma.
Universita Degli Studi Di Perugia runs clinical trials in conditions such as Hairy cell leukaemia, Malignant melanoma, Hairy cell leukaemia recurrent, Hodgkin's disease refractory, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Study of Vemurafenib and Rituximab for Untreated Hairy Cell Leukemia Patients
ItalyStudy on Short vs. Long Immunotherapy with Pembrolizumab and Nivolumab for Patients with High-Risk Skin Melanoma After Surgery
FinlandStudy of Obinutuzumab, Vemurafenib, and Cobimetinib for Hairy Cell Leukemia in Patients Previously Treated with Purine Analogs or Unfit for Chemotherapy
ItalyStudy of Ruxolitinib with Brentuximab or Pembrolizumab for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
ItalyIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
